Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts give Orchestra BioMed a “Moderate Buy” consensus: Six of eight analysts rate the stock a buy, while one rates it a hold and one a sell. The average 12-month price target is $13.00, versus a recent share price of $4.41.
• Orchestra BioMed reported a quarterly loss of $0.38 per share, slightly better than the expected $0.39 loss, but revenue of $0.09 million fell short of the $0.14 million estimate. Analysts expect a full-year loss of approximately $1.53 per share.
• Insider Darren Sherman sold 15,000 shares under a pre-arranged Rule 10b5-1 plan, while institutional ownership stands at 53.2%. The stock has traded between $2.20 and $5.42 over the past year.

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $13.00.

OBIO has been the subject of several recent research reports. Piper Sandler reissued an "overweight" rating and issued a $10.00 price target (up from $9.00) on shares of Orchestra BioMed in a research report on Tuesday. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Orchestra BioMed in a research report on Friday, July 17th. Wall Street Zen lowered Orchestra BioMed from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Orchestra BioMed in a report on Thursday, May 14th. Finally, B. Riley Financial decreased their price target on shares of Orchestra BioMed from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, May 19th.

Insider Activity at Orchestra BioMed

In related news, insider Darren Sherman sold 15,000 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $4.09, for a total transaction of $61,350.00. Following the completion of the transaction, the insider owned 1,154,327 shares in the company, valued at $4,721,197.43. The trade was a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Orchestra BioMed

Several institutional investors and hedge funds have recently bought and sold shares of OBIO. Flat Footed LLC acquired a new position in shares of Orchestra BioMed during the second quarter worth $1,084,670,000. Canada Pension Plan Investment Board purchased a new stake in shares of Orchestra BioMed during the 2nd quarter valued at $91,000. Algert Global LLC boosted its position in shares of Orchestra BioMed by 94.4% in the 2nd quarter. Algert Global LLC now owns 28,486 shares of the company's stock worth $123,000 after purchasing an additional 13,830 shares in the last quarter. BlackRock Inc. purchased a new position in Orchestra BioMed during the 2nd quarter worth $10,832,000. Finally, Deutsche Bank AG purchased a new position in Orchestra BioMed during the 2nd quarter worth $171,000. 53.20% of the stock is owned by hedge funds and other institutional investors.

Orchestra BioMed Stock Performance

Shares of NASDAQ:OBIO opened at $4.41 on Friday. The company has a market capitalization of $265.04 million, a price-to-earnings ratio of -5.19 and a beta of 0.50. Orchestra BioMed has a 52 week low of $2.20 and a 52 week high of $5.42. The company has a quick ratio of 7.01, a current ratio of 8.26 and a debt-to-equity ratio of 1.80. The firm has a 50 day moving average of $4.03 and a 200 day moving average of $4.11.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.01. The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.14 million. Orchestra BioMed had a negative return on equity of 149.61% and a negative net margin of 184.60%. On average, sell-side analysts predict that Orchestra BioMed will post -1.53 earnings per share for the current fiscal year.

About Orchestra BioMed

Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source